Assembly Biosciences Files Q1 2025 10-Q
Ticker: ASMB · Form: 10-Q · Filed: 2025-05-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, biotech, collaboration, financials
Related Tickers: GILD
TL;DR
ASMB Q1 25 10-Q filed. Cash, equity, Gilead deal updates.
AI Summary
Assembly Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business operations. Key details regarding cash, equity, and agreements with entities like Gilead Sciences Incorporated are included in the filing.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for Assembly Biosciences, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — Biotech companies often face inherent risks due to the nature of drug development and regulatory processes.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-05-08 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- ASSEMBLY BIOSCIENCES, INC. (company) — Filer of the 10-Q
- Gilead Sciences Incorporated (company) — Partner in agreements
- 20250331 (date) — End of reporting period
- 20250508 (date) — Filing date
FAQ
What were Assembly Biosciences' key financial highlights for the quarter ending March 31, 2025?
The 10-Q filing for the period ending March 31, 2025, provides detailed financial statements, but specific dollar amounts for revenue, net income, or cash flow are not explicitly listed in the provided text snippet.
What is the nature of the agreements between Assembly Biosciences and Gilead Sciences Incorporated mentioned in the filing?
The filing mentions 'Equity Agreements' and 'Option License And Collaboration Agreement' between Assembly Biosciences and Gilead Sciences Incorporated, indicating a partnership or licensing arrangement.
When did Assembly Biosciences change its name from VENTRUS BIOSCIENCES INC?
Assembly Biosciences, Inc. changed its name from VENTRUS BIOSCIENCES INC on February 11, 2008.
What is the Standard Industrial Classification (SIC) code for Assembly Biosciences?
The SIC code for Assembly Biosciences is 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Assembly Biosciences?
Assembly Biosciences' fiscal year ends on December 31.
From the Filing
0000950170-25-066991.txt : 20250508 0000950170-25-066991.hdr.sgml : 20250508 20250508161534 ACCESSION NUMBER: 0000950170-25-066991 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250508 DATE AS OF CHANGE: 20250508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 25926321 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 10-Q 1 asmb-20250331.htm 10-Q 10-Q --12-31 0001426800 Q1 false http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember 1 http://fasb.org/srt/2024#ChiefExecutiveOfficerMember 0001426800 us-gaap:CommonStockMember asmb:GileadSciencesIncorporatedMember asmb:EquityAgreementsMember 2023-10-01 2023-10-31 0001426800 srt:MinimumMember 2025-01-01 2025-03-31 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001426800 us-gaap:CommonStockMember asmb:GileadSciencesIncorporatedMember asmb:OptionLicenseAndCollaborationAgreementMember 2023-10-01 2023-10-31 0001426800 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001426800 asmb:JuneSeventeenTwoZeroTwoFourWarrantsMember 2024-01-01 2024-12-31 0001426800 2025-03-31 0001426800 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001426800 us-gaap:RetainedEarningsMember 2023-12-31 0001426800 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001426800 asmb:GileadSciencesIncorporatedMember asmb:OptionLicenseAndCollaborationAgreementMember 2024-01-01 2024-12-31 0001426800 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001426800 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001426800 asmb:ResearchAndDiscoveryMember 2024-01-01 2024-03-31 0001426800 asmb:JuneSixteenTwoZeroTwoFourWarrantsMember 2024-01-01 2024-12-31 0001426800 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001426800 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001426800 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001426800 us-gaap:CommonStockMember asmb:GileadSciencesIncorporatedMember asmb:OptionLicenseAndCollaborationAgreementMember 2025-01-01 2025-03-31 0001426800 asmb:JuneSeventeenTwoZeroTwoFourWarrantsMember 2024-12-31 0001426800 us-gaap:CommonStockMember 2024-12-31 0001426800 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001426800 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001426800 srt:MaximumMember 2024-01-01 2024-03-31 0001426800 2025-01-01 2025-03-31 0001426800 asm